Identification of NLRP3 inflammasome platforms is the main breakthrough on DCM research, as it is in the area of HF (Butts et al., 2015) and other cardiometabolic diseases (Janket et al., 2015; Mastrocola et al., 2016a). Here, NLRP3 is linked to familial dilated cardiomyopathy.